$placeNoAds is not true
placeAds(In the Statement, line 8, 'HIV AND AIDS, should be deleted, and, In the Statement, line 12, VIRAL DISORDERS, should be deleted. In the Statement, line 12, after INFECTIOUS DISEASES, OTHER THAN HIV AND AIDS should be inserted, and in the Statement, line 13, after IMMUNOLOGICAL DISORDERS, OTHER THAN HIV AND AIDS should be inserted.;Pharmaceutical preparations for the treatment and prevention of cardiovascular diseases, diabetes, obesity, cancer, endocrine disorders, hormonal diseases and disorders, urological disorders, sexual dysfunction, [ HIV and AIDS, ] central nervous systems diseases and disorders, peripheral nervous system diseases and disorders, osteoporosis, rheumatism, neurological disorders, pain, gastrointestinal disorders, respiratory diseases and disorders, allergies, bacterial disorders, [ viral disorders, ] fungal disorders, infectious diseases * other than HIV and AIDS *, inflammation and inflammatory diseases, sepsis, immunological disorders * other than HIV and AIDS *, musculoskeletal disorders, disease and disorders of the liver, allergic rhinitis, and opioid-induced constipation [ ; ] *, except pharmaceutical preparations for the treatment of viral disorders * pharmaceutical preparations for treating thrombocytopenia;In the Statement, line 8, 'HIV AND AIDS, should be deleted, and, In the Statement, line 12, VIRAL DISORDERS, should be deleted. In the Statement, line 12, after INFECTIOUS DISEASES, OTHER THAN HIV AND AIDS should be inserted, and in the Statement, line 13, after IMMUNOLOGICAL DISORDERS, OTHER THAN HIV AND AIDS should be inserted. In the statement, line 15, after constipation; , except pharmaceutical preparations for the treatment of viral disorders should be inserted.;Color is not claimed as a feature of the mark.;, 'body') is not true
LUZIPLA Brand - FindOwnerSearch

LUZIPLA

Welcome to the Brand page for “LUZIPLA”, which is offered here for In the statement, line 8, 'hiv and aids, should be deleted, and, in the statement, line 12, viral disorders, should be deleted. in the statement, line 12, after infectious diseases, other than hiv and aids should be inserted, and in the statement, line 13, after immunological disorders, other than hiv and aids should be inserted.;pharmaceutical preparations for the treatment and prevention of cardiovascular diseases, diabetes, obesity, cancer, endocrine disorders, hormonal diseases and disorders, urological disorders, sexual dysfunction, [ hiv and aids, ] central nervous systems diseases and disorders, peripheral nervous system diseases and disorders, osteoporosis, rheumatism, neurological disorders, pain, gastrointestinal disorders, respiratory diseases and disorders, allergies, bacterial disorders, [ viral disorders, ] fungal disorders, infectious diseases * other than hiv and aids *, inflammation and inflammatory diseases, sepsis, immunological disorders * other than hiv and aids *, musculoskeletal disorders, disease and disorders of the liver, allergic rhinitis, and opioid-induced constipation [ ; ] *, except pharmaceutical preparations for the treatment of viral disorders * pharmaceutical preparations for treating thrombocytopenia;in the statement, line 8, 'hiv and aids, should be deleted, and, in the statement, line 12, viral disorders, should be deleted. in the statement, line 12, after infectious diseases, other than hiv and aids should be inserted, and in the statement, line 13, after immunological disorders, other than hiv and aids should be inserted. in the statement, line 15, after constipation; , except pharmaceutical preparations for the treatment of viral disorders should be inserted.;color is not claimed as a feature of the mark.;.

Its status is currently believed to be active. Its class is unavailable. “LUZIPLA” is believed to be currently owned by “SHIONOGI & CO., LTD.”


Owner:
SHIONOGI & CO., LTD.
Owner Details
Description:
In the Statement, line 8, 'HIV AND AIDS, should be deleted, and, In the Statement, line 12, VIRAL DISORDERS, should be deleted. In the Statement, line 12, after INFECTIOUS DISEASES, OTHER THAN HIV AND AIDS should be inserted, and in the Statement, line 13, after IMMUNOLOGICAL DISORDERS, OTHER THAN HIV AND AIDS should be inserted.;Pharmaceutical preparations for the treatment and prevention of cardiovascular diseases, diabetes, obesity, cancer, endocrine disorders, hormonal diseases and disorders, urological disorders, sexual dysfunction, [ HIV and AIDS, ] central nervous systems diseases and disorders, peripheral nervous system diseases and disorders, osteoporosis, rheumatism, neurological disorders, pain, gastrointestinal disorders, respiratory diseases and disorders, allergies, bacterial disorders, [ viral disorders, ] fungal disorders, infectious diseases * other than HIV and AIDS *, inflammation and inflammatory diseases, sepsis, immunological disorders * other than HIV and AIDS *, musculoskeletal disorders, disease and disorders of the liver, allergic rhinitis, and opioid-induced constipation [ ; ] *, except pharmaceutical preparations for the treatment of viral disorders * pharmaceutical preparations for treating thrombocytopenia;In the Statement, line 8, 'HIV AND AIDS, should be deleted, and, In the Statement, line 12, VIRAL DISORDERS, should be deleted. In the Statement, line 12, after INFECTIOUS DISEASES, OTHER THAN HIV AND AIDS should be inserted, and in the Statement, line 13, after IMMUNOLOGICAL DISORDERS, OTHER THAN HIV AND AIDS should be inserted. In the statement, line 15, after constipation; , except pharmaceutical preparations for the treatment of viral disorders should be inserted.;Color is not claimed as a feature of the mark.;
Categories: STATEMENT